Effect of Hormone Resistance Type on First-Line Treatment Selection in ER+/HER2-Negative Metastatic Breast Cancer. (2026). Voprosy Onkologii, 72(3), OF-2675. https://doi.org/10.37469/0507-3758-2026-72-3-OF-2675